TY - JOUR
T1 - MicroRNAs in chronic lymphocytic leukemia
T2 - MiRacle or miRage for prognosis and targeted therapies?
AU - Van Roosbroeck, Katrien
AU - Calin, George A.
N1 - Funding Information:
Dr CalinisTheAlanM.GewirtzLeukemia&LymphomaSociety Scholar.WorkinDrCalin's laboratoryissupportedinpartbythe NIH/NCIgrants1UH2TR00943-01and1R01CA182905-01,theUT MD AndersonCancerCenterSPOREinMelanomagrantfromNCI (P50 CA093459),aDevelopmentalResearchAwardbyLeukemia SPORE P50CA100632,AimatMelanomaFoundationandthe Miriam andJimMulvaresearchfunds,theBrainSPORE (2P50CA127001),theCenterforradiationOncologyResearch Project,theCenterforCancerEpigeneticsPilotproject,a2014 KnowledgeGAPMDACCgrant,aCLLMoonshotpilotproject,the UT MD AndersonCancerCenterDuncanFamilyInstituteforCancer PreventionandRiskAssessment,aSINFgrantincoloncancer,the LauraandJohnArnoldFoundation,theRGKFoundationandthe EstateofC.G.Johnson,Jr.
Funding Information:
Dr Calin is The Alan M. Gewirtz Leukemia & Lymphoma Society Scholar. Work in Dr Calin’s laboratory is supported in part by the NIH/NCI grants 1UH2TR00943-01 and 1 R01 CA182905-01, the UT MD Anderson Cancer Center SPORE in Melanoma grant from NCI (P50 CA093459), a Developmental Research Award by Leukemia SPORE P50 CA100632, Aim at Melanoma Foundation and the Miriam and Jim Mulva research funds, the Brain SPORE (2P50CA127001), the Center for radiation Oncology Research Project, the Center for Cancer Epigenetics Pilot project, a 2014 Knowledge GAP MDACC grant, a CLL Moonshot pilot project, the UT MD Anderson Cancer Center Duncan Family Institute for Cancer Prevention and Risk Assessment, a SINF grant in colon cancer, the Laura and John Arnold Foundation, the RGK Foundation and the Estate of C. G. Johnson, Jr.
Publisher Copyright:
© 2016 Elsevier Inc. All rights reserved.
PY - 2016/4/1
Y1 - 2016/4/1
N2 - Chronic lymphocytic leukemia (CLL) is a heterogeneous disease and has a highly variable clinical course with survival ranging from a couple of months to several decades. MicroRNAs (miRNAs), small non-coding RNAs that regulate transcription and translation of genes, have been found to be involved in CLL initiation, progression, and resistance to therapy. In addition, they can be used as prognostic biomarkers and as targets for novel therapies. In this review, we describe the association between miRNAs and the cytogenetic aberrations commonly found in CLL, as well as with other prognostic factors. We describe the presence of miRNAs as extracellular entities in the plasma and serum of CLL patients and discuss their role in resistance to therapy. Finally, we will explore the potential of targeted miRNA therapy for the treatment of CLL, with a special emphasis on MRX34, the first miRNA mimic that is currently being evaluated for clinical use.
AB - Chronic lymphocytic leukemia (CLL) is a heterogeneous disease and has a highly variable clinical course with survival ranging from a couple of months to several decades. MicroRNAs (miRNAs), small non-coding RNAs that regulate transcription and translation of genes, have been found to be involved in CLL initiation, progression, and resistance to therapy. In addition, they can be used as prognostic biomarkers and as targets for novel therapies. In this review, we describe the association between miRNAs and the cytogenetic aberrations commonly found in CLL, as well as with other prognostic factors. We describe the presence of miRNAs as extracellular entities in the plasma and serum of CLL patients and discuss their role in resistance to therapy. Finally, we will explore the potential of targeted miRNA therapy for the treatment of CLL, with a special emphasis on MRX34, the first miRNA mimic that is currently being evaluated for clinical use.
KW - Biomarker
KW - Chronic lymphocytic leukemia
KW - MIR-34 mimic
KW - MicroRNA
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=84960976366&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960976366&partnerID=8YFLogxK
U2 - 10.1053/j.seminoncol.2016.02.015
DO - 10.1053/j.seminoncol.2016.02.015
M3 - Review article
C2 - 27040698
AN - SCOPUS:84960976366
SN - 0093-7754
VL - 43
SP - 209
EP - 214
JO - Seminars in oncology
JF - Seminars in oncology
IS - 2
ER -